DECHENG CAPITAL
Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
DECHENG CAPITAL
Social Links:
Industry:
Financial Services Health Care Venture Capital
Founded:
2012-01-01
Status:
Active
Contact:
(650) 233-0688
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Nginx
Similar Organizations
Echo Health Ventures
Echo Health Ventures is a venture capital firm that focuses on investing in health care companies.
Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Upstream Bio | Decheng Capital investment in Series A - Upstream Bio | 200 M USD |
| 2022-06-02 | Watchmaker Genomics | Decheng Capital investment in Series A - Watchmaker Genomics | 40 M USD |
| 2022-05-17 | Mirvie | Decheng Capital investment in Series B - Mirvie | 45 M USD |
| 2022-05-12 | USCI medical laboratory | Decheng Capital investment in Private Equity Round - USCI medical laboratory | N/A |
| 2022-02-17 | Nalu Medical | Decheng Capital investment in Venture Round - Nalu Medical | 104 M USD |
| 2022-01-20 | ImmPACT Bio | Decheng Capital investment in Series B - ImmPACT Bio | 111 M USD |
| 2021-12-27 | Kind Pharmaceutical | Decheng Capital investment in Series B - Kind Pharmaceutical | 50 M USD |
| 2021-11-16 | ACELYRIN | Decheng Capital investment in Series B - ACELYRIN | 250 M USD |
| 2021-09-15 | Alpine Immune Sciences | Decheng Capital investment in Post-IPO Equity - Alpine Immune Sciences | 91 M USD |
| 2021-09-09 | Mammoth Biosciences | Decheng Capital investment in Series D - Mammoth Biosciences | 150 M USD |
More informations about "Decheng Capital"
Decheng Capital - Crunchbase Investor Profile
Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of …See details»
Decheng Capital
Decheng Capital. Decheng Capital About Us; Team; Portfolio; News; Contact; A Global Life Sciences Investment Firm. Established in 2012. $2.1 Billion of Capital. ... Cellares Raises …See details»
Decheng Capital - LinkedIn
Decheng Capital | 1,336 followers on LinkedIn. Global life sciences firm investing in revolutionary life sciences and rapid growth healthcare companies. | Decheng Capital is a leading investment ...See details»
Decheng Capital Investor Profile: Portfolio & Exits
Decheng Capital General Information Company Description. Founded in 2012, Decheng Capital is a venture capital firm based in Menlo Park, California. The firm seeks to invest in early-stage life science companies and growth stage …See details»
Decheng Capital - Investments, Portfolio & Company Exits
Decheng Capital 's most notable exits include Terns Pharmaceuticals, ... Which industries has this organization had the most exits in? Show . Terns Pharmaceuticals Terns Pharmaceuticals is a …See details»
List of top Decheng Capital Portfolio Companies - Crunchbase
Decheng Capital is a venture capital firm that provides capital to early and growth stage life science companies. This list of organizations invested in by Decheng Capital provides data on …See details»
Decheng Capital
Prior to founding Decheng Capital in 2011, Dr. Cui spent 5 years at Bay City Capital, a leading international life science venture capital firm in San Francisco. He was previously Director of Strategic Investment for the Southern Research …See details»
Decheng Capital Global Life Sciences Fund IV - PitchBook
Decheng Capital Global Life Sciences Fund IV is a 2021 vintage venture capital fund managed by Decheng Capital. The fund is located in Menlo Park, California and invest globally. The fund …See details»
Cellares Raises $82M To Solve The Biggest Hurdles In …
May 5, 2021 Decheng Capital and Eclipse Ventures lead Series B round, bringing total funding to over $100 million. SOUTH SAN FRANCISCO, May 5th, 2021 – Cellares Corporation, a life sciences technology company that …See details»
Decheng Capital 13F annual report (2024) - wallmine
$326 billion Assets Under Management (AUM) As of 7th August 2024, Decheng Capital’s top holding is 5,458,810 shares of Cg Oncology Inc currently worth over $172 billion and making …See details»
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock …
Mar 25, 2024 Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025; ... Following the closing of …See details»
Decheng Capital
Decheng Capital. Decheng Capital About Us; Team; Portfolio; News; Contact; A Global Life Sciences Investment Firm. Established in 2012. $2.1 Billion of Capital. ... Apexigen and …See details»
Decheng Capital - Funding, Financials, Valuation & Investors
Decheng Capital has raised a total of $1B across 4 funds, their latest being Decheng Capital Global Life Sciences Fund IV. This fund was announced on Dec 17, 2020 and raised a total of …See details»
China’s Decheng Capital Looks to Raise $650m for Global Life …
Dec 17, 2020 Decheng Capital, an investment firm that focuses on the life sciences and healthcare sectors, is raising $650 million for a new fund, Decheng Capital Global Life …See details»
DECHENG CAPITAL LLC Top 13F Holdings - WhaleWisdom.com
Decheng Capital is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,977,628,753 (Form ADV from 2024-08-14). Their last reported 13F filing for Q3 …See details»
Decheng Capital Files for $700 Million Global Life Sciences Fund
Jun 18, 2024 Decheng Capital announced plans for a $700 million global life sciences fund, its fifth life sciences vehicle. The company, which has offices in Silicon Valley, Shanghai and New …See details»
Decheng Capital - Contacts, Employees, Board Members
Decheng Capital has 6 current employee profiles, including Founder and Managing Director Min Cui. Contacts. Edit Contacts Section. Job Department. Protected Content. Founder and …See details»
Life sciences investor Decheng Capital targets $700M for fifth fund
Jun 17, 2024 Min Cui, Decheng Capital founder. June 17, 2024 01:48 PM EDT. Financing. Startups. Life sciences investor Decheng Capital targets $700M for fifth fund. Kyle LaHucik …See details»
Paris dreams of becoming the capital of positive AI with the ...
20 hours ago France will host 100 heads of state and some 600 business and NGO leaders from the USA and Europe, as well as China and Africa.See details»
Founder and Managing Director @ Decheng Capital - Crunchbase
Min Cui, PhD, is the Founder and Managing Director of Decheng Capital. He is a member of the Board of Directors of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb …See details»